MedTrace Logo

Registry of Patients with Suspected Amyloidosis in Heart Failure

NCT05176548 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2024-10-01

No results posted yet for this study

Summary

Observational multicenter registry of cohorts with follow-up.

Patients with heart failure, age ≥ 18 years, with clinical suspicion of cardiac amyloidosis and any LVEF value, treated in the field of Internal Medicine.

Initially, a duration of two years was established to recruit at least 150 patients in the group with AC, and a follow-up of two years.

Upon completion of the two years of follow-up, the continuity or completion of the registry will be assessed.

Conditions

Interventions

DIAGNOSTIC_TEST

Bone-cardiac scintigraphy

Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Prado Salamanca-Bautista, MD, PhD · Hospital Universitario Virgen Macarena

  • Rocio Ruiz-Hueso, MD · Hospital Universitario Virgen Macarena

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2024-03-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05176548 on ClinicalTrials.gov